282 related articles for article (PubMed ID: 21194873)
1. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats.
Burkhardt WA; Guscetti F; Boretti FS; Ivos Todesco A; Aldajarov N; Lutz TA; Reusch CE; Sieber-Ruckstuhl NS
Domest Anim Endocrinol; 2011 Apr; 40(3):155-64. PubMed ID: 21194873
[TBL] [Abstract][Full Text] [Related]
2. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Vaughan MA; Feldman EC; Hoar BR; Nelson RW
J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
[TBL] [Abstract][Full Text] [Related]
4. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane.
Reusch CE; Sieber-Ruckstuhl N; Wenger M; Lutz H; Perren A; Pospischil A
Vet Rec; 2007 Feb; 160(7):219-24. PubMed ID: 17308018
[TBL] [Abstract][Full Text] [Related]
5. Persistent isolated hypocortisolism following brief treatment with trilostane.
Ramsey IK; Richardson J; Lenard Z; Tebb AJ; Irwin PJ
Aust Vet J; 2008 Dec; 86(12):491-5. PubMed ID: 19076773
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
7. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
8. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Mantis P; Lamb CR; Witt AL; Neiger R
Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
[TBL] [Abstract][Full Text] [Related]
9. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy.
Witt AL; Neiger R
Vet Rec; 2004 Mar; 154(13):399-400. PubMed ID: 15083974
[No Abstract] [Full Text] [Related]
10. The use of trilostane for the treatment of alopecia X in Alaskan malamutes.
Leone F; Cerundolo R; Vercelli A; Lloyd DH
J Am Anim Hosp Assoc; 2005; 41(5):336-42. PubMed ID: 16141187
[TBL] [Abstract][Full Text] [Related]
11. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis.
Teshima T; Hara Y; Takekoshi S; Nezu Y; Harada Y; Yogo T; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):32-44. PubMed ID: 19041802
[TBL] [Abstract][Full Text] [Related]
12. Determination of the concentrations of trilostane and ketotrilostane that inhibit ex vivo canine adrenal gland synthesis of cortisol, corticosterone, and aldosterone.
McGraw AL; Whitley EM; Lee HP; Boothe DM; Behrend EN
Am J Vet Res; 2011 May; 72(5):661-5. PubMed ID: 21529218
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.
Bonadio CM; Feldman EC; Cohen TA; Kass PH
J Vet Intern Med; 2014; 28(4):1239-43. PubMed ID: 24863172
[TBL] [Abstract][Full Text] [Related]
16. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Kenefick SJ; Neiger R
J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
18. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
19. Trilostane in dogs.
Ramsey IK
Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):269-83. PubMed ID: 20219488
[TBL] [Abstract][Full Text] [Related]
20. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.
Bell R; Neiger R; McGrotty Y; Ramsey IK
Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
